CAS has migrated to this web app on 5/23/21. If you have an active membership on 5/23/21, log in with your email and password. Otherwise, please create a new account.
Webinar Series of the Chinese Antibody Society
We don't have any active meetings as of now. New meetings will show up here as registration opens. Check back soon!
Sign in to view recordings
01/08/2023
Dr. Li Peng
Immune checkpoint blockade has revolutionized cancer treatment. However, most patients encounter resistance not yet overcome by existing therapeutic approaches, urging the need for innovative therapies. Sialoglycans have emerged as a new dimension of immune checkpoints on various tumors that impair immune response. Cleaving off sialoglycans from tumors using a tumor-associated …
11/19/2022
Dr. Weifeng Xu
Biotherapeutics such as mAbs are immunogenic hence can induce anti-drug Abs (ADA) including neutralizing ADA (NAb). These ADA/NAb can induce broad side-effects such as injection site overreaction, reduced exposure, to life-threatening endogenous counterpart neutralization and allergic response. Hence immunogenicity testing including ADA screening, confirmation and titer as well as NAb …
11/17/2022
Richard Liqun Wang Ph. D., MBA.
As we moved to the 21st century, more new therapy modalities have emerged. Among them, CAR-T cell therapies have recently gained marketing approval and opened new opportunities to save lives of refractory and relapsed cancer patients. At the same time, we have to be aware of the commercial limitation on …
09/24/2022
Dr. Tianlei Ying
Nanobodies are typically obtained by immunizing camels or alpacas, and their animal-derived components have potential safety risks in clinical applications. In recent years, Dr. Ying’s team has developed the research and development platform for fully human nanobodies based on fully human germline genes. The team found that, due to their …